{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:05:53Z","timestamp":1778785553809,"version":"3.51.4"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T00:00:00Z","timestamp":1322006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:sec><jats:label\/><jats:p>\n              <jats:bold>To cite this article:<\/jats:bold> Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, Br\u00e4utigam M, Klimek L. A randomized placebo\u2010controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. <jats:italic>Allergy<\/jats:italic> 2012; <jats:bold>67<\/jats:bold>: 272\u2013279.<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract:<\/jats:title><jats:p>\n              <jats:bold>Background:\u2002<\/jats:bold> Specific subcutaneous immunotherapy (SCIT) for seasonal rhinoconjunctivitis with unmodified allergen extracts is effective, but limited by risk of side\u2010effects and involves treatment over 3\u2003years. We examined a depigmented polymerized grass pollen extract for immunogenicity and for clinical efficacy in a rush preseasonal regimen.<\/jats:p><jats:p>\n              <jats:bold>Methods:\u2002<\/jats:bold> Depigmented polymerized grass pollen extract was tested for proliferation and cytokine production by peripheral blood mononuclear cells. A prospective, double\u2010blind, placebo\u2010controlled trial of 195 grass pollen allergic patients treated with preseasonal rush immunotherapy using depigmented polymerized allergenic extract of mixed grass pollen was performed over 2\u2003years. Primary outcome was combined symptom and medication score (SMS) during the peak of the second grass pollen season. Secondary outcomes included combined score over the whole season, during the first grass pollen season, individual symptom and medication scores, quality of life, well days\/hell days and responder analysis. Adverse events were classified using the EAACI scale. Grass pollen\u2010specific IgE and IgG4 were measured before and during treatment.<\/jats:p><jats:p>\n              <jats:bold>Results:\u2002<\/jats:bold> Depigmented polymerized extract stimulated dose\u2010dependent T\u2010cell proliferation and cytokine production. Patients treated with preseasonal SCIT showed improved combined scores during peak season at year 2 (median 3.93, interquartile range 0.77\u20136.27 <jats:italic>vs<\/jats:italic> median 5.86 for placebo, 3.11\u20138.36, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01). Most secondary outcomes were significantly better for active treatment. Side\u2010effects were minimal, with no grade 3 or 4 reactions.<\/jats:p><jats:p>\n              <jats:bold>Conclusions:\u2002<\/jats:bold> Depigmented polymerized grass pollen extract is immunogenic and clinically effective in rush preseasonal SCIT. This form of immunotherapy may be an attractive option for some patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1398-9995.2011.02736.x","type":"journal-article","created":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T09:13:02Z","timestamp":1322039582000},"page":"272-279","source":"Crossref","is-referenced-by-count":60,"title":["A randomized placebo\u2010controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy*"],"prefix":"10.1111","volume":"67","author":[{"given":"O.","family":"Pfaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Urry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. S.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Hawrylowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Br\u00e4utigam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,23]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00013904"},{"key":"e_1_2_8_3_2","first-page":"CD001936","article-title":"Allergen injection immunotherapy for seasonal allergic rhinitis","author":"Calderon MA","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01620.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01219_1.x"},{"key":"e_1_2_8_6_2","first-page":"455","article-title":"Adverse effects and fatalities associated with subcutaneous allergen immunotherapy","volume":"21","author":"Bukantz SC","year":"2008","journal-title":"Clin Allergy Immunol"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.060"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(92)90129-P"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.11.014"},{"key":"e_1_2_8_10_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000230518","article-title":"Preparation and properties of,allergoids, derived from native pollen allergens by mild formalin treatment","volume":"41","author":"Marsh DG","year":"1971","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(85)90661-X"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000110888"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2010.31.3334"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00862.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.07.043"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02413.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2010.03521.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02687.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70190-8"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.056006498.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00790.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.23625.x"},{"key":"e_1_2_8_23_2","unstructured":"Commitee for medicinal products for human use (CHMP).Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. Lodon: CHMP\/EWP\/18504\/2006;2008."},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01312.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2011.02.004"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.10.044"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1991.tb00807.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1998.00407.x"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000024233"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2003.00240.x"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908123410702"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.035"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02041.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.07.046"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2011.02736.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2011.02736.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:37:01Z","timestamp":1695472621000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2011.02736.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,23]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1398-9995.2011.02736.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02736.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,23]]}}}